Coastlands Capital LP filed an initial statement of beneficial ownership (Form 3) with the SEC on November 6, 2026, disclosing holdings in Bolt Biotherapeutics, Inc. (NASDAQ:BOLT) as of the event date of November 6, 2026.

Key Highlights

  • Common Stock: Coastlands Capital LP reported indirect beneficial ownership of 412,416 shares of common stock, held by Coastlands Capital LP.
  • Series D Preferred Stock: Coastlands also reported indirect beneficial ownership of Series D Non-Voting Convertible Preferred Stock convertible into 1,166,275 shares of common stock, subject to stockholder approval and a 4.99% beneficial ownership cap.
  • Warrants: Coastlands reported indirect beneficial ownership of warrants to purchase 583,138 shares of common stock at an exercise price of $8.5743, also subject to the 4.99% cap.
  • 10% Owner: The filing identifies Coastlands Capital LP as a 10% owner of Bolt Biotherapeutics, Inc.
  • Control Person: According to the filing, Matthew Perry is identified as the control person of Coastlands, the Partnership, Coastlands GP, and the General Partner.
  • Warrant Expiration: The warrants expire on the earlier of 30 days following the issuer's first public disclosure of top-line results from first-in-human clinical data from its Program 2 Phase 1 (IL-31 bispecific) or June 30, 2028.

Coastlands Capital LP's Initial Beneficial Ownership in Bolt Biotherapeutics

According to the filing, Coastlands Capital LP submitted a Form 3 initial statement of beneficial ownership on November 6, 2026, disclosing three categories of securities in Bolt Biotherapeutics, Inc. (NASDAQ:BOLT). All holdings are reported as indirectly owned by Coastlands Capital LP. The filing states that Coastlands Capital LP and Coastlands Capital GP LLC serve as the investment adviser and general partner, respectively, of Coastlands Capital Partners LP, which is the entity through which the holdings are held.

The filing discloses 412,416 shares of common stock held indirectly. In addition, Coastlands reported Series D Non-Voting Convertible Preferred Stock that, following stockholder approval of its conversion, would automatically convert into 1,166,275 shares of common stock at a ratio of 1,000 shares of common stock per preferred share, subject to a limitation that Coastlands and its affiliates may not convert if doing so would result in beneficial ownership exceeding 4.99% of outstanding common stock. The Series D Preferred Stock carries no expiration date, according to the filing.

The filing also discloses warrants to purchase 583,138 shares of common stock at an exercise price of $8.5743. The filing states these warrants become exercisable following the automatic conversion of the Series D Preferred Stock into common stock upon receipt of stockholder approval. The same 4.99% beneficial ownership cap applies to the exercise of these warrants. The filing notes that each reporting person "disclaims beneficial ownership of common stock except to the extent of that person's pecuniary interest therein."

What Was Disclosed

Coastlands Capital LP filed an initial beneficial ownership statement disclosing indirect holdings in Bolt Biotherapeutics, Inc. consisting of 412,416 common shares, Series D Preferred Stock convertible into 1,166,275 common shares, and warrants for 583,138 common shares at $8.5743, all subject to a 4.99% ownership cap.